Who We Are

Built on 80 years of experience, SK pharmteco is a trusted partner specializing in the manufacture of APIs and intermediates, cell and gene therapy technologies, registered starting materials and analytical services for the pharmaceutical industry worldwide. Our global operations have the capability and capacity to support your needs from development through commercial production.

Our complementary assets and expertise enable us to provide the highest quality services to our customers.

SK pharmteco's Cell & Gene Therapy

Discover how we can address your CGT needs​

SK pharmteco's SmartPlatform Portfolio

An integrated solution for every CDMO process 

Our Services

SK pharmteco is a global contract development and manufacturing organization (CDMO) with 7 manufacturing facilities across the U.S., Europe, and Korea. The company partners with biopharmaceutical companies to manufacture Active Pharmaceutical Ingredients (API) and intermediates, cell and gene therapy technologies, registered starting materials, and to perform analytical services. SK pharmteco is a subsidiary of SK Inc. (KRX: 034730) (SK), the strategic investment company for SK Group, South Korea’s second-largest conglomerate.

SK pharmteco is a leader in operational excellence and continuous improvement. Our highly skilled team delivers innovative solutions utilizing advanced technologies:

We provide PAI and full regulatory support as well as complete confidentiality. We have a strong record of environmental, health, and safety performance. All our plants have been successfully audited by global regulatory agencies including the FDA (US), EMA (Europe), PMDA (Japan), and MFDS (Korea). 

With a strong technology toolbox and ~1,000 m³ (~265,000 gal) of global small molecule capacity and two facilities dedicated to large molecules, we have the capability and capacity to support your needs across the full lifecycle.

The most trusted global partner in the delivery of innovative medicine

We are committed to changing the world through our unwavering dedication to life-saving therapies.
We enable our partners with cutting-edge technology, expertise and customer centricity, allowing them to bring breakthrough treatments to patients and delivering happiness and health to stakeholders everywhere.

Global Presence

7 Manufacturing Sites

Small Molecule Manufacturing
3 US, 1 Ireland, 1 Korea
~1,000 m³ (~265,000 gal)
Cell and Gene Therapy Manufacturing
1 US, 1 France

5 R&D Centers

2 US, 1 Ireland, 1 France, 1 Korea

Analytical Support

~80 Years of Experience

~2,000 Highly Skilled and Talented Workforce

approved by global regulatory agencies

FDA, EMA, ANSM, PMDA, MFDS

Advanced
Technologies

Diazomethane, Azide, Hydrazine, Ozone

Fixed bed, CSTR, PAT

Process Development, CGT Analysis, Viral Vector Development & CGMP Manufacturing, Plasmid DNA Manufacturing, & Cell Therapy Manufacturing

Simulated Moving Bed (SMB), Batch

Up to 4 m(~1,000 gal) scale 

Down to 10 ng/mcontainment 

Schedule II-V Manufacturing  

Schedule I By Request

Crystallization, Micronization 

News & Events

Contact Us

For Business Development & Marketing Enquires contact
Scroll to Top

Enter your details to access Marketing Materials